+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA



Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA



European Heart Journal 32(18): 2282-2289



In anticoagulation treatment with warfarin, the risk of thrombo-embolic events must be weighed against the risk of bleeding. Time in therapeutic range (TTR) is an important tool to assess the quality of anticoagulation treatment, and has been shown to correlate with less bleeding and thrombo-embolic complications. AuriculA, the Swedish national quality registry for atrial fibrillation and anticoagulation, is used for follow-up and dosage control of warfarin. This is the first report of TTR in AuriculA and, in a subgroup of two centres, bleeding and thrombo-embolic complications during 2008. Prothrombin complex (International normalized ratio) values from 18 391 patients in 67 different centres were analysed. The mean (SD) age was 70 (12) years. The main indications for warfarin treatment were: atrial fibrillation (64%), venous thromboembolism (19%), and heart valve dysfunction (13%). Time in therapeutic range for all patients was 76.2%. The mean weekly dose of warfarin decreased with age and TTR increased with age. In 4273 patients from two centres in AuriculA, the frequency of major bleedings and venous/arterial thrombo-embolism were 2.6 and 1.7% and for atrial fibrillation, 2.6 and 1.4%, per treatment year, respectively. A correlation between age and the risk of major bleeding (P< 0.001), but not thrombo-embolic complications (P= 0.147), was seen. Compared with prospective randomized trials of warfarin treatment, TTR in the AuriculA population was higher. Complications were low, probably due to the organization of anticoagulation treatment in Sweden. Use of the AuriculA dosing programme could have contributed to the results by keeping dosing regimens consistent over all centres.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036203510

Download citation: RISBibTeXText

PMID: 21616951

DOI: 10.1093/eurheartj/ehr134


Related references

Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Clinical and Applied Thrombosis/Hemostasis 23(5): 445-453, 2017

Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology 32(10): 1247.E23-1247.E28, 2016

Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range. Circulation. Cardiovascular Interventions 6(4): 444-451, 2013

Risk analysis of thrombo-embolic and recurrent bleeding events in the management of intracranial haemorrhage due to oral anticoagulation. Acta Chirurgica Belgica 105(3): 268-274, 2005

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children. Journal of Thrombosis and Haemostasis 9(5): 1090-1092, 2011

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2331-2332, 2012

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2332-2333, 2012

Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation. Journal of Cardiology 68(6): 517-522, 2016

Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circulation. Cardiovascular Quality and Outcomes 4(1): 22-29, 2011

Thrombo-embolic and bleeding complications in patients with mechanical valve replacements - a prospective observational study. SAMJ (South African Medical Journal) 96(8): 710-713, 2006

Left atrial appendage occlusion with the Amplatzer Cardiac Plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk. Acta Cardiologica 71(2): 135-143, 2016

Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. Journal of Thrombosis and Thrombolysis 15(3): 213-216, 2003

Ulcer healing time and antibiotic treatment before and after the introduction of the Registry of Ulcer Treatment: an improvement project in a national quality registry in Sweden. Bmj Open 3(8): E003091, 2013

Prophylaxis of thrombo-embolic complications in major surgery of the hip joint. A comparative controlled study with subcutaneous calcium heparinate and acetylsalicylic acid. Munchener Medizinische Wochenschrift 115(44): 1967-1970, 1973

Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circulation. Cardiovascular Quality and Outcomes 7(5): 664-669, 2014